Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

X4 Pharmaceuticals Inc

XFOR ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Pharmaceuticals ·

USA Small Cap Analyst: STRONG BUY

Last Close

$3.50

▼ -0.28%

Market Cap $347.01M · Vol 174.36K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$347.01M

Small Cap

Div Yield

N/A

EPS Growth

+64.28%

YoY

RSI (14)

24.30

Momentum

Beta

0.45

vs Market

52W High

$4.83

27.25% below

52W Low

$2.80

25.36% above

Volume

174.36K

Avg 228.79K

P/B

1.95

Price-to-book

ROE

-75.99%

Return on equity

Free Float

91.49%

Public shares

Shariah Compliance8 STANDARDS

✗ X4 Pharmaceuticals Inc (XFOR) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does XFOR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+2.94%

-18.60%

-13.58%

-17.26%

YTD

-12.50%

+15.13%

-89.49%

-97.79%

Financials & Valuation

TTM · Annual

Total Revenue	$35.11M
Net Income	$-79,199,000.00
Revenue Growth (YoY)	+346.33%
Gross Margin	83.60%
Operating Margin	-247.44%
Net Profit Margin	-225.55%
ROE	-75.99%
ROA · ROIC	-36.24% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	4.82
P/B	1.95
P/FCF	N/A
EPS Growth	+64.28%
Outstanding Shares	99.15M

Technical Indicators

50-Day SMA	$3.99
200-Day SMA	$3.93
RSI (14)	24.30
Beta	0.45
52-Week High	$4.83
52-Week Low	$2.80

Volume Today	174.36K
Avg Daily Volume (30D)	228.79K
Relative Volume	0.76x
Volatility (10D)	79.12
Volatility (30D)	65.00
Free Float	91.49%

Analyst Consensus

STRONG BUY

Current Price $3.50

Mean Target $11.60

52W Low$2.80 52W High$4.83

Current

Target

$2.80 $4.83

Current Analyst target

+231.43% upside potential · 5 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001TCY1B7

ISINUS98420X2027

CountryUSA

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Company +1.28% JNJ Johnson & Johnson +1.10% ABBV AbbVie Inc. +0.58% NVS Novartis AG +1.60% NOVN.S Novartis AG +1.52%

Company Profile

X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.